Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2022

View Archived Issues

NPC1L1 gene polymorphisms tied to coronary artery calcification

Novel series of glucosylceramide synthase inhibitors presented for treating Parkinson's disease

FDA clears IND for BiOneCure's anti-Trop-2 ADC, BIO-106

BETR-001 shows antidepressant activity in preclinical models

NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in models of HF

Discovery of noncovalent peptidomimetic proteasome inhibitors for the treatment of MM

Alternate approach could enable earlier detection, intervention, in Alzheimer's

HitGen and Uppthera extend their PROTAC collaboration

Harbour BioMed and AstraZeneca enter global outlicense agreement for HBM-7022

T cell-intrinsic AR activity drives IFN-gamma suppression and immunotherapy resistance

Peptidomimetic TMPRSS2 inhibitor shows prophylactic and therapeutic activity against SARS-CoV-2 VOCs

Medshine Discovery patents new sGC activators

Sunshine Lake Pharma discloses thyroid hormone receptor beta agonists

Aurigene Discovery Technologies presents CREBBP and/or KAT3B inhibitors

Merck & Co. synthesizes new GLCT-1 inhibitors

New TYK2 inhibitors identified by Esker Therapeutics

Emergex collaborates with nonprofit organization to advance yellow fever booster vaccine candidate

IKZF1 gain-of-function variants tied to T/B cell-related immune dysregulation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.